Quizartinib is an FLT3 inhibitor. It’s specifically made for AML patients who’ve relapsed or don’t respond to treatment, and have FLT3-ITD mutations. It works by blocking FLT3 signaling.
You can get the drug in two doses: 17.7 mg and 26.5 mg, both in film-coated tablets. The first dose you should start with is 53 mg, taken once a day after a little lead-up time. Quizartinib comes in bottles with 28 tablets each.
